stockrowSolventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.
- Revenue
- −7.01%
- EPS
- −101.0%
- Free cash flow
- +561.9%
- Total debt
- −90.1%
Quarter to September 2026, against a year earlier
Follow SOLV
Alert me
Solventum Corporation 10-Q filed May 5, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 6, 2025: 19 added · 48 removed · 30 modified; 9 with only figures updated; 1 moved without change
-
Modified
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with Solventum Corporation's ("Solventum," "we," "our," "us," or the
Company’s"Company") condensed consolidated financial statements and corresponding notes elsewhere in this Quarterly Report on Form 10-Q. The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Solventum for theninethree months endedSeptember 30March 31,20252026 and20242025. For full understanding of the Company’s financial condition and results of operations, thebelowdiscussion below should be read alongside the Management's Discussion and Analysis of Financial Condition and Results of Operations included in the Company’s20242025 Annual Report on Form 10-K. This discussion contains forward-looking statements that are based upon current expectations and are subject to uncertainty and changes in circumstances. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors, including those discussed below and elsewhere in this Quarterly Report on Form 10-Q, and particularly in Item 1A, “Risk Factors” in the Company’s20242025 Annual Report on Form 10-K.